Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Shareholder Meeting (May 2010)
14 slides from Neuren Pharmaceuticals's shareholder meeting presentation, May 25, 2010
Slide 1: Neuren Pharmaceuticals Annual Shareholders' Meeting May 2010
For personal use only Neuren Pharmaceuticals Annual Shareholders’ Meeting May 2010
Slide 2: 2009: A Watershed Year for Neuren
2009: A Watershed Year for Neuren Prioritized focus on NNZ-2566 and Motiva™ For personal use only Reduced operating costs Obtained approval and Fast Track designation for NNZ-2566 IND Secured a further $14 million in non-dilutive funding from U.S. Army (US$18m total) Established subsidiary
Slide 3: Positioned for Success
Positioned for Success For personal use only Strong clinical candidates in neurology – Two drugs in Phase II clinical trials for CNS indications – Opportunities to leverage NNZ-2566 in niche indications • Chemo therapy induced ototoxicity and neuropathy • Non-convulsive seizures associated with br
Slide 4: Focused pipeline with two dynamic clinical programs
Focused pipeline with two dynamic clinical programs Motiva™ (nefiracetam) For personal use only – Treatment for psychiatric and behavioral effects of stroke, TBI and other chronic CNS disorders – Clinical efficacy data in multiple Phase II and III trials including Phase IIb under US IND – Phase II
Slide 5: NNZ-2566
NNZ-2566 Composition For personal use only – Synthetic analogue of IGF-1(1-3) – composition of matter and method of use patent issued: expires in 2023 Multiple modes of action – Molecular: inhibits inflammatory cytokine and apoptotic gene expression – Cellular: inhibits microglial activation and
Slide 6: Major Concern with No Available Therapy
Major Concern with No Available Therapy Large and growing problem For personal use only – Traumatic brain injuries (TBIs) account for 1.7 million hospital visits and 52,000 deaths each year -- almost a third of injury-related fatalities in the U.S. – Major cause of accidental death among young peo
Slide 7: Non-convulsive Seizures (NCS): Secondary Injuries
Non-convulsive Seizures (NCS): Secondary Injuries NCS are associated with significantly worse outcomes in TBI For personal use only patients – Frequently lead to spreading cortical depression, status epilepticus and death – Not effectively prevented or treated with anti-epileptic drugs Dual stra
Slide 8: Leading Edge TBI Program
Leading Edge TBI Program Dose-dependent efficacy in all brain injury models For personal use only – Penetrating and concussive TBI, NCS, 2 focal stroke and 1 global HI model – Models with hemorrhagic, hypoxic, ischemic, reperfusion components – Therapeutic time window: up to 4 hrs in TBI; up to 7
Slide 9: Motiva (nefiracetam) Overview
Motiva™ (nefiracetam) Overview Origins For personal use only – Drug licensed from Daiichi by Hamilton Pharmaceuticals – Belongs to well-known class of compounds (acetams) – Well-characterized effects in neurobehavioural, cognition, epilepsy models – Safety confirmed in 1,700+ patients in multiple
Slide 10: Apathy: Prevalence in Multiple Disorders
Apathy: Prevalence in Multiple Disorders For personal use only Schizophrenia Post Stoke 67% 35% Depression 20% Post-TBI Apathy 50% Parkinson’s 40% Frontotemporal Dementia Alzheimer’s 75% 55%
Slide 11: Drugs in Development for Apathy as Primary or Secondary Endpoint
Drugs in Development for Apathy as Primary or Secondary Endpoint Study Sponsor For personal use only Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia Novartis (CHoPA-I) Carbidopa/Levodopa/Entacapone Verses Immediate Release (IR) Novartis Carbidopa/Levodopa on Non-Motor Symptoms in
Slide 12: Perseis Therapeutics: Profile
Perseis Therapeutics: Profile Developing antibody therapeutics for the treatment of breast For personal use only and other cancers – Established April 2009 by Neuren Pharmaceuticals and the Breast Cancer Research Trust – Seed funding of NZ$1.18M from Breast Cancer Research Trust – New Zealand Comp
Slide 13: TFF-3 role in breast cancer survival
TFF-3 role in breast cancer survival For personal use only 13
Slide 14: Further Information
Further Information For personal use only New Zealand USA Level 2, 57 Wellington Street 3 Bethesda Metro Center, Suite 700 Freemans Bay 1011, Auckland Bethesda, Maryland 20814 USA New Zealand Larry Glass, CEO +64 (9) 3700 200 +1 (301) 941 1830 1 800 259 181 (Australia Freephone) lglass@neurenpharma.
Neuren Pharmaceuticals — Shareholder Meeting (May 2010) on 6ix